The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2861-2869

  Milne, Roger L ^a   Osorio, Ana ^a   Cajal, Teresa Ramón Y ^e   Vega, Ana ^d   Llort, Gemma ^g   De La Hoya, Miguel ^b   Díez, Orland ^f,h   Carmen Alonso, M ^e   Lazaro, Conxi ⁱ   Blanco, Ignacio ^g   Sánchez de Abajo, Ana ^b   Caldés, Trinidad ^b   Blanco, Ana ^d   Graña, Begoña ^j,k   Durán, Mercedes ^l   Velasco, Eladio ^l   Chirivella, Isabel ^m   Cardeñosa, Eva Esteban ⁿ   Tejada, María Isabel ^q   Beristain, Elena ^q   Miramar, María Dolores ^r   Calvo, María Teresa ^r   Martínez, Eduardo ^o   Guillén, Carmen ^p   Salazar, Raquel ^s   Román, Carlos San ^c   Antoniou, Antonis C ^t   Urioste, Miguel ^a,d   Benítez, Javier ^a,d   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e Servicio de Oncologia Medica

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL DURAN I REYNALS   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j Instituto de Salud Carlos III   (Spain)

^k HOSPITAL JOSEP TRUETA   (Spain)

^l UNIVERSITY OF VALLADOLID   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^p MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^q HOSPITAL DE CRUCES   (Spain)

^r HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^s Centro de Investigacion del Cancer   (Spain)

^t UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DECISION MAKING; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARIECTOMY; OVARY CANCER; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; SPAIN; BREAST TUMOR; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; MULTICENTER STUDY; MUTATION; OVARY TUMOR; RISK FACTOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PENETRANCE; RISK FACTORS; SPAIN;

EID: 52049095304     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4436     Document Type: Article

References (46)

1. Diez O, Osorio A, Duran M, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 2003;22:301-12.
2. Easton DF. Familial risks of breast cancer. Breast Cancer Res 2002;4:179-81.
3. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 2006;84:16-28.
4. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
5. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-36.
6. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-8.
7. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
8. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-71.
9. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
10. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741 - 7.
11. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
12. Marroni F, Aretini P, D'Andrea E, et al. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004;12:899-906.
13. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
14. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18:173-90.
15. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE; Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
16. Ford D, Easton DF, Stratton M, et al.; The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
17. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11-5.
18. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002;2:113-23.
19. Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467-73.
20. Lubinski J, Phelan CM, Ghadirian P, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004;3:1-10.
21. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
22. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst 2006;98:116-22.
23. Jenkins MA, Southey MC, Giles GG, Hopper JL. Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer. Curr Oncol Rep 2007;9:202-7.
24. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII. Lyon: IARC Press; 2002.
25. Beristain E, Martinez-Bouzas C, Guerra I, et al. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 2007;106:255-62.
26. Llort G, Munoz CY, Tuser MP, et al. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 2002;19:307.
27. Infante M, Duran M, Esteban-Cardenosa E, Miner C, Velasco E. High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). J Hum Genet 2006;51:611-7.
28. Filippini S, Blanco A, Fernandez-Marmiesse A, et al. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families. BMC Med Genet 2007;8:40.
29. Velasco E, Infante M, Duran M, et al. Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiexon genes. Nat Protoc 2007;2:237-46.
30. de la Hoya M, Gutierrez-Enriquez S, Velasco E, et al. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem 2006;52:1480-5.
31. Gutierrez-Enriquez S, de La Hoya M, Martinez-Bouzas C, et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 2007;103:103-7.
32. Judkins T, Hendrickson BC, Deffenbaugh AM, Scholl T. Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 2005;573:168-79.
33. Mazoyer S, Dunning AM, Serova O, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
34. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001;21:1-18.
35. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 1988;5:471-2.
36. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 2002;11:2805-14.
37. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5.
38. Diez O, Osorio A, Robledo M, et al. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br J Cancer 1999;79:1302-3.
39. Marugame T, Katanoda K. International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol 2006;36:399-400.
40. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
41. Antoniou AC, Pharoah PD, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005;42:602-3.
42. Vega A, Campos B, Bressac-De-Paillerets B, et al. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001;17:520-1.
43. Vega A, Torres M, Martinez JI, Ruiz-Ponte C, Barros F, Carracedo A. Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. Ann Hum Genet 2002;66:29-36.
44. Hemminki K, Bermejo JL. Effects of screening for breast cancer on its age-incidence relationships and familial risk. Int J Cancer 2005;117:145-9.
45. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Bio-markers Prev 2002;11:329-36.
46. Al-Saffar M, Foulkes WD. Hereditary ovarian cancer resulting from a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: is the OCCR useful clinically? J Med Genet 2002;39:e68.